Argonautica Private Wealth Management Inc. Increases Stake in Eli Lilly and Company (NYSE:LLY)

Argonautica Private Wealth Management Inc. increased its holdings in Eli Lilly and Company (NYSE:LLY) by 0.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,192 shares of the company’s stock after purchasing an additional 13 shares during the quarter. Argonautica Private Wealth Management Inc.’s holdings in Eli Lilly and Company were worth $2,464,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. AMF Tjanstepension AB increased its position in shares of Eli Lilly and Company by 113.7% during the third quarter. AMF Tjanstepension AB now owns 331,786 shares of the company’s stock valued at $293,964,000 after buying an additional 176,552 shares during the period. Values Added Financial LLC boosted its position in Eli Lilly and Company by 4.9% during the 3rd quarter. Values Added Financial LLC now owns 366 shares of the company’s stock valued at $324,000 after acquiring an additional 17 shares in the last quarter. Cavalier Investments LLC grew its holdings in shares of Eli Lilly and Company by 211.1% during the 3rd quarter. Cavalier Investments LLC now owns 32,556 shares of the company’s stock worth $28,843,000 after acquiring an additional 22,090 shares during the period. Peterson Wealth Advisors LLC raised its position in shares of Eli Lilly and Company by 8.5% in the 3rd quarter. Peterson Wealth Advisors LLC now owns 716 shares of the company’s stock worth $634,000 after acquiring an additional 56 shares in the last quarter. Finally, Kercheville Advisors LLC lifted its stake in shares of Eli Lilly and Company by 10.3% in the 3rd quarter. Kercheville Advisors LLC now owns 8,540 shares of the company’s stock valued at $7,566,000 after purchasing an additional 795 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 2.4 %

LLY opened at $902.47 on Wednesday. The stock has a market capitalization of $855.69 billion, a price-to-earnings ratio of 77.07, a PEG ratio of 1.40 and a beta of 0.42. The firm has a 50 day moving average price of $805.87 and a 200-day moving average price of $847.99. Eli Lilly and Company has a twelve month low of $711.40 and a twelve month high of $972.53. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Equities research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be given a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 0.66%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.30. The ex-dividend date is Friday, February 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 51.24%.

Eli Lilly and Company declared that its Board of Directors has authorized a stock buyback program on Monday, December 9th that allows the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization allows the company to buy up to 2% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s leadership believes its shares are undervalued.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on LLY shares. Redburn Atlantic upgraded Eli Lilly and Company to a “hold” rating in a report on Monday, November 4th. Barclays decreased their price target on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a research note on Thursday, October 31st. Wolfe Research started coverage on shares of Eli Lilly and Company in a research note on Friday, November 15th. They set an “outperform” rating and a $1,000.00 price objective on the stock. Berenberg Bank set a $970.00 price objective on shares of Eli Lilly and Company in a report on Thursday, January 16th. Finally, Bank of America reiterated a “buy” rating and set a $997.00 target price on shares of Eli Lilly and Company in a report on Tuesday, December 10th. Three research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,000.28.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.